Resource Library

Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach

These consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring bring together existing and new clinical and programmatic recommendations across different ages, populations and settings, bringing together all relevant WHO guidance on HIV produced since 2016. It serves as an update to the previous edition of the consolidated guidelines on HIV.

Normative Guidance/Policies, Service Delivery

WHO recommends the Dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection

This article announces the WHO's recommendation that the dapivirine vaginal ring may be offered as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches.

Community/Advocacy, Normative Guidance/Policies

IAS 2021 Satellite Session: Bringing the Dual Prevention Pill to Market: Opportunities for HIV and Pregnancy Prevention and Implications for Future MPTs

This video-recorded session from IAS 2021 examines opportunities for bringing the Dual Prevention Pill to market as well as implications for future multipurpose prevention technologies.

The Future of ARV-Based Prevention and More

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Community/Advocacy

PEPFAR Panorama Spotlight

PEPFAR's Panorama Spotlight tracks program results achieved through PEPFAR support

Monitoring & Evaluation

PEPFAR – US Department of State

Through PEPFAR, or the The United States President’s Emergency Plan for AIDS Relief, the U.S. government has invested about $100 billion into the global HIV/AIDS response. In doing so, the Office of the U.S. Global AIDS Coordinator and Global Health Diplomacy, which manages PEPFAR, has provided a number of resources, from reports, to an outline…

Monitoring & Evaluation, Normative Guidance/Policies

Easier and Equitable Access to PrEP: How DSD can help get us there

Easier and Equitable Access to PrEP is an article written by AVAC's Director of Product Introduction and Access, Jessica Rodrigues. It elaborates on the impact of oral PrEP on the HIV pandemic and the current modifications underway to make oral PrEP more accessible to people. Differentiated Services Delivery is a method that provides oral PrEP…

Demand Creation/Marketing, Service Delivery

Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study

Widespread adoption of WHO PrEP recommendations coincided with a global increase in PrEP use. Although the 2020 global PrEP target will be missed, strong future growth in PrEP use is possible. New PrEP products could expand the PrEP user base, and, with greater expansion of oral PrEP, further adoption of WHO PrEP recommendations, and simplified…

Normative Guidance/Policies, Research, Service Delivery

Health system adaptations and considerations to facilitate optimal oral pre-exposure prophylaxis scale-up in sub-Saharan Africa

Countries in sub-Saharan Africa have progressively scaled up oral PrEP as part of combination HIV prevention. Initial scale-up efforts have generated progress, drawing lessons from existing HIV interventions, such as antiretroviral therapy and biomedical prevention. However, beset by unprepared health systems, scale-up has been slow. This review synthesises literature on essential considerations for PrEP scale-up,…

Normative Guidance/Policies, Research, Service Delivery

Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring

These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antiretroviral therapy (ART) among people living with HIV who are being treated for tuberculosis.

Normative Guidance/Policies